News and Trends 3 Aug 2022 Poseida Therapeutics and Roche to focus on therapies for hematologic malignancies Poseida Therapeutics, Inc. has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel off-the-shelf cell therapies against targets in multiple myeloma, B-cell lymphomas and other hematologic indications. “We are excited […] August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest Allarity Therapeutics, after meeting with the US Food and Drug Administration (FDA), has decided a growth factor receptor drug it licensed from Novartis is no longer commercially viable or in the best interests of its shareholders. A type C advisory meeting was held between Allarity and the FDA to discuss a development path for dovitinib. […] August 3, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 3 Aug 2022 Allarity Therapeutics takes advice from its board and switches focus to combination therapies US-based Allarity Therapeutics has made a decision to change tack and focus on combination therapy approaches while making the most of its current assets. The company says the new strategy, driven by its board of directors, aligns with the ongoing shift in oncology standard-of-care moving away from monotherapies. Instead it will veer towards more promising […] August 3, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 AbCellera and Atlas Venture to collaborate on new company for therapeutic antibody discovery AbCellera and Atlas Venture have announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ track record in forming innovative biotech companies, and AbCellera’s ability to quickly deliver lead drug candidates to bring transformational new medicines […] August 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Deciphering the molecular mechanisms of severe COVID-19 Researchers from Fujita Health University School of Medicine in Japan have been investigating COVID-19 to lead to therapeutic options against the severe form of the condition. Levels of proinflammatory cytokines are dramatically elevated in severe COVID-19 patients, the molecular mechanisms of which remain unclear. In a recent article in mBio, the researchers elucidated the role […] August 3, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Chinese biotech Sironax closes $200M funding round Sironax, an emerging Chinese biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, has completed $200 million in series B financing. The round was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors including Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, […] August 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 3 Aug 2022 Orca Bio announces Precision-T phase 3 study open and enrolling patients across US transplant centers US-based Orca Bio, today announced Precision-T, its pivotal phase 3 study, is open, enrolling and treating 174 leukemia patients at more than 20 clinical trial sites. Precision-T is a randomized, open-label multi-center study that is evaluating the safety and efficacy of Orca Bio’s lead investigational high-precision cell therapy, Orca-T, compared to standard of care allogeneic […] August 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 siRNA company Eleven Therapeutics seals $22M funding Eleven Therapeutics has raised a total of $22 million in seed funding. Among the roster of funders is the Bill & Melinda Gates Foundation, which committed $9 million in funding to Eleven, including $5 million towards future equity investment supporting the development of a first-of-its-kind platform that designs small interfering RNAs (siRNAs) with ultra-long durability […] August 3, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 3 Aug 2022 The biggest European biotech investments in July 2022 The mRNA firm Normax Biomed snagged Europe’s biggest private biotech investment in July 2022, with runners-up including AgomAb and Tropic Biosciences. Life sciences manufacturing companies saw a big windfall in Europe in July 2022 as the Cork-based Normax Biomed bagged around $301 million. The firm is establishing modular manufacturing facilities that could provide mRNA vaccines […] August 3, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Enrollment completed for trial looking at treatment of diabetic kidney disease Enrollment has been completed for a study of a regenerative cell therapy investigational product for intra-renal artery administration to treat diabetic kidney disease (DKD). U.S.-based Caladrius Biosciences Inc., a clinical-stage biopharma company that develops therapies designed to treat or reverse disease, made the announcement today (August 2). The phase 1b open-label, proof-of-concept study will look […] August 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 New monkeypox tracing method can analyze multiple samples and quickly detect virus strains Dutch company Molecular Biology Systems (MBS), in collaboration with Amsterdam University Medical Center, and researchers from the Danish Rigshospitalet, has developed a fast typing method to trace monkeypox. The new method, NextGenPCR, not only detects strains of the virus quickly, it allows for analysis of multiple samples simultaneously. This way, the inventors say, genetic characterization […] August 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Aug 2022 Success across the board for C4X Discovery Holdings plc and its partnerships Drug discovery company C4X Discovery Holdings plc released a report today (August 2) detailing the continued success of its relationship with partners across its portfolio. The company says it is happy to report it received its first milestone payment last month of €3 million ($3.1 million) from Sanofi under the out-licensing agreement for its IL-17A […] August 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email